The prognostic importance of epigenetic subgroups in patients from the UK CLL4, ARC, and ADM clinical trials. n-CLL, i-CLL, and m-CLL, classified by pyrosequencing, are depicted in green, orange, and blue, respectively. Kaplan-Meier survival curves for the 3 epigenetic subgroups for PFS (A) and OS (B) in CLL4 and for PFS in ARC/ADM cases (C). (A) The median PFS was 23, 35, and 33 months for the n-CLL (n = 186), i-CLL (n = 125), and m-CLL (n = 48) subtypes, respectively. (B) Median OS was 62.8, 66.5, and 105.9 months for n-CLL (n = 186), i-CLL (n = 125), and m-CLL (n = 48), respectively. (C) Median PFS for n-CLL (n = 112), i-CLL (n = 70), and m-CLL (n = 64) was 30.4 months, 85.4 months, and not reached, respectively. The P values are derived from Kaplan-Meier analysis with log-rank test.